Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
By hypothesising that Interstitial Cystitis is an allergic disorder of the urogenital system
that is linked to mast-cells, current therapy with omalizumab may represent a potential non
symptomatic strategy for the treatment of IC/BPS